North America Drug Delivery Market Size, Share, Growth and Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of North America drug delivery Market

The North America drug delivery market was valued at USD 702.04 billion in 2024, is projected to reach USD 743.20 billion in 2025, and is expected to grow to USD 1,175.47 billion by 2032, exhibiting a steady CAGR of 6.8% during the forecast period (2025-2032).

Drug delivery technologies play a pivotal role in ensuring that medications are administered effectively, safely, and in the correct dosage. This includes a wide range of formulations-tablets, syrups, capsules, and injectables-designed to deliver therapeutic compounds efficiently to the targeted site. The North American market is driven by a combination of growing chronic disease prevalence, technological advancements in biologics, and rising adoption of connected and smart drug delivery systems.

Key players such as BD, Novartis AG, Baxter, West Pharmaceutical Services, Inc., and Novo Nordisk are investing heavily in R&D, digital innovation, and manufacturing expansion to meet increasing patient demand for precision, convenience, and personalized care.

Market Dynamics

Drivers - Rising Chronic Conditions and Aging Population

The aging population and the increasing prevalence of chronic diseases, such as diabetes, cardiovascular conditions, and autoimmune disorders, are major growth drivers for the North American drug delivery market. Elderly populations often require long-term, consistent therapy with simplified, ergonomic devices that improve adherence.

For example, in August 2023, Kakao Healthcare partnered with Novo Nordisk to advance AI-based diabetes management services that integrate smart drug delivery for better patient outcomes. Additionally, the growing preference for at-home treatments and wearable injectors-such as insulin pumps and autoinjectors-has fueled market expansion.

LTS LOHMANN Therapie-Systeme AG's acquisition of Eitan Medical's wearable injection business in April 2023 further emphasizes the market's pivot toward large-molecule injectables and home-based care solutions.

Restraints - High Regulatory Compliance Costs

The high cost of regulatory compliance and extended product validation timelines remain significant challenges. Each drug delivery product must undergo stability testing, human factor studies, labeling reviews, and safety assessments, leading to high costs and delayed product launches. Smaller companies, in particular, struggle with these barriers, which slow innovation.

According to Cancer Research UK, completing all phases of clinical trials for a new drug can take 10-15 years, illustrating the financial and temporal burden on market entrants.

Opportunities - Surge in Connected Drug Delivery Systems

The future of North America's drug delivery lies in connected systems that combine medical devices with Bluetooth, NFC, and mobile apps for real-time monitoring. These solutions track medication adherence, measure dosage accuracy, and transmit data to healthcare providers-enhancing treatment efficiency and patient engagement.

For instance, in March 2023, Diabeloop collaborated with Novo Nordisk to create an AI-powered automated insulin delivery device. Such partnerships are accelerating the integration of digital health, data analytics, and personalized medicine into traditional drug delivery frameworks.

Challenges - Device Recalls and Quality Control Issues

Frequent device recalls due to technical malfunctions or safety concerns present ongoing risks. In October 2024, Medtronic recalled its insulin pumps due to irregular dosing and battery issues, underscoring how even minor defects can trigger costly recalls and litigation. As drug delivery devices become more complex, maintaining quality standards is increasingly critical.

Market Trends

Personalized and Smart Delivery Systems

The North American market is shifting toward patient-centric and personalized therapies. Advances in pharmacogenomics, AI-driven dosage optimization, and 3D-printed oral formulations are improving patient adherence and therapeutic accuracy.

A notable milestone occurred in February 2021, when Triastek, Inc. received FDA approval for T19, a 3D-printed rheumatoid arthritis drug, demonstrating the potential of digital manufacturing in oral drug delivery.

In injectables, smart devices such as autoinjectors, wearable injectors, and prefilled syringes are incorporating sensors to monitor administration precision and share data securely with providers, aligning with the growing focus on digital therapeutics and remote care.

Segmentation Insights

By Type

The injectable segment dominated the market in 2024, driven by the rising use of biologics, targeted therapies, and specialty drugs. Companies like Amneal Pharmaceuticals launched over 39 new injectable products in 2023, highlighting growing adoption.

The oral segment also maintains substantial demand due to ease of administration and high patient compliance, particularly for chronic diseases like diabetes and hypertension.

By Device Type

Conventional devices held the largest share in 2025 due to their affordability and availability. However, advanced devices-including connected autoinjectors and wearable systems-are expected to grow fastest, driven by R&D in biologics and precision medicine.

In April 2025, Novartis announced a USD 23 billion investment to expand its U.S. drug delivery manufacturing capabilities, signaling large-scale industry transformation.

By Application

The immune system segment dominated in 2024, supported by R&D in autoimmune and inflammatory disease treatments. Meanwhile, the endocrine system segment, primarily focused on diabetes and thyroid disorders, is projected to grow fastest through 2032.

By Distribution Channel

Hospital pharmacies accounted for the largest share in 2024, handling complex biologics and specialty drugs. However, retail pharmacies are expected to post the highest CAGR due to expanding healthcare networks and new retail health initiatives.

In June 2025, CVS Health announced a USD 20 billion investment over 10 years to integrate high-tech healthcare solutions and digital pharmacy services.

Regional Insights

United States

The U.S. leads the market with a valuation of USD 656.60 billion in 2024, fueled by strong R&D, advanced healthcare infrastructure, and high adoption of biologics and digital drug delivery devices. In August 2025, AbbVie announced a USD 195 million investment to expand API production, highlighting continued growth in domestic pharmaceutical manufacturing.

Canada

Canada is projected to register the fastest CAGR through 2032, supported by expanding clinical trials and investments in precision medicine. In January 2025, AstraZeneca announced a USD 570 million investment to develop a new clinical research facility, further strengthening its pharmaceutical innovation landscape.

Competitive Landscape

Key players in the North American drug delivery market are focusing on product innovation, mergers, and strategic partnerships to expand their footprint.

Prominent companies include:

• BD (U.S.)
• Catalent, Inc. (U.S.)
• Baxter (U.S.)
• West Pharmaceutical Services (U.S.)
• Gerresheimer AG (Germany)
• Ypsomed (Switzerland)
• Medtronic (Ireland)
• Nemera (France)

Recent Developments:

• Dec 2024: Novo Holdings A/S acquired Catalent for USD 16.5 billion.
• Oct 2024: Nemera launched a reusable auto-injector for chronic diseases at CPhI Milan.
• Apr 2024: Baxter gained FDA clearance for its Novum IQ infusion system, enhancing intelligent infusion therapy.

Conclusion

The North America drug delivery market is poised for robust expansion, driven by aging demographics, biologics innovation, and the adoption of connected delivery technologies. Although regulatory complexities and quality control remain challenges, continuous R&D and digital integration will shape the next generation of smart, patient-centric drug delivery systems.

Market Size Overview:

• 2024: USD 702.04 Billion
• 2025: USD 743.20 Billion
• 2032: USD 1,175.47 Billion
• CAGR (2025-2032): 6.8%

Segmentation By Type

• Oral
  • Tablet
    • Oral Dispersible Tablets (ODTs)
    • Modified Release Tablets
    • Coated Tablets
    • Others
  • Capsules
  • Liquid or Syrup
  • Others
• InjectableConventional Injectables
  • Conventional Injectables
  • Pre-filled Syringes
  • Auto-injectors
  • Pen-injectors
  • Wearable Injectors
  • Others

By Device Type

• Conventional
• Advanced

By Application Area

• Central Nervous System (CNS)
• Digestive System (Metabolism)
• Endocrine System
• Immune System
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• North America (By Service Type, Processing Type, Delivery Mode, Method, End-user, and Country)
  • U.S.
  • Canada